Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 20,581,978 $ 24,637,295
Other receivable from joint venture 633,408 93,253
Prepaid expenses and other current assets 97,033 36,745
Total Current Assets 21,312,419 24,767,293
Patent costs 1,725,853 1,577,421
Total Assets 23,038,272 26,344,714
Current Liabilities    
Accounts payable and accrued liabilities 1,195,892 258,056
Investee losses in excess of investment 490,726 218,263
Total Current Liabilities 1,686,618 476,319
Commitments and contingencies - (Note 5)
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares:
Common stock, $0.001 par value, 8,333,333 authorized, 3,249,353 shares and 2,738,508 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively (1) 3,249 2,738
Additional paid-in capital 133,701,433 129,359,799
Accumulated deficit (112,356,480) (103,497,622)
Total Stockholders' Equity 21,351,654 25,868,395
Total Liabilities and Stockholders' Equity 23,038,272 26,344,714
Series A Preferred Stock    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: 785 813
Total Stockholders' Equity 785  
Series B Preferred Stock    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: 2,667 $ 2,667
Total Stockholders' Equity $ 2,667